FDA Grants Accelerated Approval to Lynozyfic™ (linvoseltamab-gcpt) for Relapsed/Refractory Multiple Myeloma Read more about FDA Grants Accelerated Approval to Lynozyfic™ (linvoseltamab-gcpt) for Relapsed/Refractory Multiple Myeloma Add new comment
The IMF Proudly Announces the Completion of EMA-CHMP”s Qualification Advice to i2TEAMM Novel Biomarker Procedure Application on the Use of MRDnegCR as an Intermediate Early Endpoint for Conditional Market Approval in Myeloma Clinical Trials Read more about The IMF Proudly Announces the Completion of EMA-CHMP”s Qualification Advice to i2TEAMM Novel Biomarker Procedure Application on the Use of MRDnegCR as an Intermediate Early Endpoint for Conditional Market Approval in Myeloma Clinical TrialsAdd new comment
FDA Eliminates REMS Program for Certain Autologous CAR T-cell Therapies Read more about FDA Eliminates REMS Program for Certain Autologous CAR T-cell TherapiesAdd new comment
FDA Removes Required REMS Program for Approval of Abecma (ide-cel) and for Breyanzi (liso-cel) Read more about FDA Removes Required REMS Program for Approval of Abecma (ide-cel) and for Breyanzi (liso-cel)Add new comment
From Oncology Nursing News: "Q&A: Transitioning Myeloma Care to the Community Level" Read more about From Oncology Nursing News: "Q&A: Transitioning Myeloma Care to the Community Level"Add new comment
Bipartisan Cancer Drug Parity Act Reintroduced to Lower Costs for Oral Cancer Drugs Read more about Bipartisan Cancer Drug Parity Act Reintroduced to Lower Costs for Oral Cancer DrugsAdd new comment
European CHMP Recommends Sarclisa (isatuximab-irfc) for Approval to Treat Transplant-Eligible Newly Diagnosed Multiple Myeloma Read more about European CHMP Recommends Sarclisa (isatuximab-irfc) for Approval to Treat Transplant-Eligible Newly Diagnosed Multiple Myeloma Add new comment
Darzalex (daratumumab) Receives Positive Opinion from European CHMP for High-Risk Smoldering Multiple Myeloma Patients Read more about Darzalex (daratumumab) Receives Positive Opinion from European CHMP for High-Risk Smoldering Multiple Myeloma PatientsAdd new comment
June 2025 – Myeloma News from the Journals Read more about June 2025 – Myeloma News from the JournalsAdd new comment
The International Myeloma Society and the IMF’s International Myeloma Working Group collaborate on Consensus Definition of High-Risk Multiple Myeloma Read more about The International Myeloma Society and the IMF’s International Myeloma Working Group collaborate on Consensus Definition of High-Risk Multiple MyelomaAdd new comment
